Treatment Persistence With Subcutaneous Biologic Therapies in Patients With Psoriatic Arthritis (Psa).

Background • Psoriatic arthritis (PsA) is an inflammatory peripheral and/or axial arthritis associated with psoriasis, usually seronegative for rheumatoid factors1 • Patients with PsA also have debilitating skin disease, and nearly half may also have a spinal disease.2 PsA is estimated to affect 2.0% to 3.0% of the general population3 • To date, few studies have examined treatment persistence of subcutaneous biologics in a real-world setting in Europe, specifically in Germany Objectives • To examine persistence on therapy over 12 months for PsA patients who were newly treated with subcutaneous biologics • To assess if there are differences in treatment persistence between patients with and without prior DMARD experience